GM-CSF and Whole Cells

Reference work entry

Abstract

Granulocyte-macrophage colony stimulating factor (GM-CSF) is a pleiotropic cytokine critical to immune homeostasis, capable of both pro-inflammatory and tolerance-inducing properties. GM-CSF has a variety of current and potential clinical applications, including use as a growth factor for myeloid cell recovery after chemotherapy, as a cancer vaccine adjuvant, and in combinatorial immunotherapy with monoclonal antibodies.

Keywords

Acute myeloid leukemia (AML) Granulocyte-macrophage colony-stimulating factor (GM-CSF) Assessment Biology of CALGB study Idiotype vaccines In cancer Preclinical studies PROSTVAC-VF Protein vaccination Therapeutics Peripheral blood mononuclear cells (PBMC) 

References

  1. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–8.CrossRefPubMedGoogle Scholar
  2. Ai WZ, Tibshirani R, Taidi B, et al. Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood. 2009;113:5743–6.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Disis ML, Schiffman K, Guthrie K, et al. Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein–based vaccine. J Clin Oncol. 2004;22:1916–25.CrossRefPubMedGoogle Scholar
  4. Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009;27:4685–92.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Freedman A, Neelapu SS, Nichols C, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009;27:3036–43.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8:533–44.CrossRefPubMedGoogle Scholar
  7. Ho VT, Vanneman M, Kim H, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci. 2009;106:15825–30.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci. 2008;105:3005–10.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014;321:1744–53.CrossRefGoogle Scholar
  10. Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony stimulating factor-secreting tumor cell vaccines. Immunol Rev. 2008;222:287–98.CrossRefPubMedGoogle Scholar
  11. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010a;363:411–22.CrossRefPubMedGoogle Scholar
  12. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010b;28:1099–105.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Lawson DH, Lee S, Zhao F, et al. Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol. 2015;33:4066–76.Google Scholar
  14. Levy R, Ganjoo KN, Leonard JP, et al. Active idiotypic vaccination versus control immunotherapy for folliculiar lymphoma. J Clin Oncol. 2014;32:1797–803.Google Scholar
  15. Madan R, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012. doi:10.1016/S1470-2045(12)70006-2. published online Feb 10, 2012.PubMedGoogle Scholar
  16. Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer. 2010;10:425–34.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773–8.CrossRefPubMedGoogle Scholar
  18. Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:949–54.PubMedGoogle Scholar
  19. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86:457–62.PubMedGoogle Scholar
  20. Schuster SJ, Neepalu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011;29:2787–94.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Slingluff Jr CL, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21:4016–26.CrossRefPubMedGoogle Scholar
  22. Slingluff Jr CL, Petroni GR, Olson W, et al. Helper T-Cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 2008;26:4973–80.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Slingluff Jr CL, Petroni GR, Olson WC, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009;15:7036–44.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995;332:1671–7.CrossRefPubMedGoogle Scholar
  25. Van den Eertwegh AJM, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012. doi:10.1016/S1470-2045(12)70007-4. published online Feb 10. 2012.PubMedGoogle Scholar
  26. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute and Department of MedicineBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  2. 2.Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute and Department of MedicineBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations